MedPath

Digestive Tract Cancer and CIPN

Not Applicable
Recruiting
Conditions
Remote Exercise
Digestive Tract Cancer
Chemotherapy-induced Peripheral Neuropathy
Interventions
Other: regular care group
Other: supervised exercise therapy group
Other: remote home-based exercise therapy group
Registration Number
NCT06331962
Lead Sponsor
National Cheng-Kung University Hospital
Brief Summary

According to the incidence rate of cancer, the digestive tract cancer accounts for two of the top ten cancers. It also accounts for half of the top ten causes of cancer death. Chemotherapy remains one of the most common forms of cancer treatment, and chemotherapy-induced peripheral neuropathy (CIPN) is one of the common adverse effects of cancer treatment in cancer survivors. To date, there is no exercise guideline established for patients with CIPN; therefore, CIPN remains quite threatening to cancer survivors. Due to limited studies on effects of exercise on improvement of CIPN symptoms in patients with digestive tract cancers, this study aims to investigate the effects of exercise and different intervention delivery modes (remote home exercise and exercise under supervision) at different time points on the CIPN symptoms, body inflammatory index, physical function, and quality of life of gastrointestinal cancer survivors with chemotherapy-induced peripheral neuropathy.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
90
Inclusion Criteria
  1. Age 20 and above;
  2. Diagnosed by a physician with gastrointestinal cancer and has undergone chemotherapy or is currently undergoing chemotherapy;
  3. Diagnosed by a physician with chemotherapy-induced peripheral neuropathy.
Exclusion Criteria
  1. Cognitive impairment or inability to cooperate with verbal instructions;
  2. Neurological, muscular, skeletal, or cardiovascular issues preventing participation in exercise training;
  3. Age 80 or above;
  4. Refusal to engage in exercise intervention or participate in data collection.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
regular care groupregular care groupPerform regular care for eight consecutive weeks. After the tracking period ends (8 weeks), provide home-based education on resistance exercises, cardiovascular endurance exercises, and sensory training exercises.
supervised exercise therapy groupsupervised exercise therapy groupExercise Location and Frequency: Physiotherapy Center (twice a week) and individual's home (twice a week). Exercise Duration: Eight weeks (subject to adjustments based on actual progress), with a total exercise time of 40 minutes each session. Exercise Components: Cardiovascular endurance exercise, resistance training, sensory training exercises. The home-based exercise training content is partially the same as the remote home-based exercise group.
remote home-based exercise therapy groupremote home-based exercise therapy groupLocation and Frequency: Four times per week at the individual's own home. Exercise Duration: Eight weeks (subject to adjustments based on actual progress), with a total exercise time of 40 minutes each session. Exercise Components: Cardiovascular endurance exercise, resistance training, sensory exercises. Note: The participant will receive a customized exercise plan based on their capabilities, including guidelines and exercise instructions (exercise names, required equipment, movement sequences, repetitions, precautions).
Primary Outcome Measures
NameTimeMethod
body weightbaseline, 4-week intervention, 8-week intervention, and 3 month after intervention

body weight in kg

body heightbaseline, 4-week intervention, 8-week intervention, and 3 month after intervention

body height in m

genebaseline

gene

body mass indexbaseline, 4-week intervention, 8-week intervention, and 3 month after intervention

body mass index in kg/m2

Basic informationbaseline, 4-week intervention, 8-week intervention, and 3 month after intervention

Gender, date of birth, education level, survival days and status, exercise habit, alcohol consume history, smoking history, type of cancer, stage of cancer, start date of chemotherapy, number of chemotherapy sessions prior to intervention, chemotherapy drugs used, study period, and the subjects' medical history.

blood databaseline, 4-week intervention, 8-week intervention, and 3 month after intervention

blood data, including blood cell count, neutrophils, lymphocytes, monocytes, hemoglobin, albumin, magnesium, mean corpuscular volume, etc.

Questionnaire of Chemotherapy-Induced Peripheral Neuropathybaseline, 4-week intervention, 8-week intervention, and 3 month after intervention

The European Organisation for Research and Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy 20-item scale (CIPN-20) assesses sensory abnormalities in patients. Scores range from 0 to 80, with 0 indicating no abnormalities and 80 severe abnormalities. Lower scores indicate better outcomes, while higher scores indicate worse outcomes. The total score is calculated by adding scores from items 1 to 19, ranging from 19 to 76, termed the CIPN20 sum1-19 score. Item 20 evaluates male impotence, relevant only for males. Additionally, items are categorized into sensory (1, 2, 3, 4, 5, 6, 9, 10, and 18), motor (7, 8, 11, 12, 13, 14, 15, and 19), and autonomic (16, 17, and 20) subscales.

Questionnaire of Quality of Lifebaseline, 4-week intervention, 8-week intervention, and 3 month after intervention

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) is to assess the quality of life. The transferred score range for this tool is typically from 0 to 100, where 0 indicates very poor quality of life, and 100 indicates very good quality of life. There are five aspects in the QLQ-C30, including physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning. In this scoring system, higher scores generally indicate better quality of life, while lower scores suggest poorer quality of life.

Secondary Outcome Measures
NameTimeMethod
Sensation Testbaseline, 4-week intervention, 8-week intervention, and 3 month after intervention

Assess sensory issues from neuropathy using Romberg test

Muscle Strengthbaseline, 4-week intervention, 8-week intervention, and 3 month after intervention

Evaluate muscle strength using grip strength assessment device. Participant grips device withdominant hand using maximum effort.

Cardiovascular Endurancebaseline, 4-week intervention, 8-week intervention, and 3 month after intervention

Assess using 2-min step test. Participant steps in place for 2 mins, feet higher thanmidpoint between patella and iliac spine. Tester notes successful steps in 2 mins.

Dynamic Balancebaseline, 4-week intervention, 8-week intervention, and 3 month after intervention

Use Timed Up \& Go (TUG) test. Participant stands from chair upon signal, walks 3m at normal pace,returns, and sits. Time recorded

Trial Locations

Locations (1)

Department of Physical Therapy, National Cheng-Kung University

🇨🇳

Tainan, Taiwan

© Copyright 2025. All Rights Reserved by MedPath